Formerly Summit Biosciences Inc. | KDD’s Post

As drugs become more complex, so do the routes to their development. Read our latest Expert Insights by Veranova's Global Vice President R&D Operations at Veranova Kishore Hotha, Ph.D., entitled 'Mastering the Molecule' which explores the advancements in analytical drug testing that allow #CDMOs such as Veranova to manage your complex chemistries with confidence: https://lnkd.in/ewVwWNy9

Oral factor VIIIa mimetic drug Inno8 showing good response in trials. Let's hope for success of this revolutionary step in the management of hemophilia. https://lnkd.in/dtSqqnCz

Ready for a paradigm shift?!....Nutriband Inc. striving to create the world's first and only abuse deterrent technology for use on all transdermal products with risk of abuse. This type of technology deployment has an opportunity to reduce accidental exposures as well. Kindeva Drug Delivery's Fentanyl patch, along with their incredible experience in the transdermal space made for an efficient development and market entry approach. Here is to a transformative 2024 for Nutriband Inc.!

Participated as delegate in one-day National Conference on 'Nano Based Drug Delivery Systems; Recent Developements and Future Prospects' under NILA-2023: Module 14

In this Pod with CEO Magnus Corfitzen and Deputy CEO Julie Waras Brogren you can hear more about what’s next for Orviglance and Ascelia Pharma AB in 2024. Key topics include the upcoming headline results for Orviglance phase 3 study by May 2024 and our recent financing. #asceliapharma #update

I am currently at #swissbiotechday Meet me to discuss about mimicking clinical endpoints #invitro for treating #musculoskeletal conditions in #bone affected by #inflammation, #cancer, and #geneticmutations.

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Four burning questions about the future of the $16.5B Novo-Catalent deal: To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both. Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private. It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement. Why did Novo do this? Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk. Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said. “Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.” While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs. Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy. The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.” As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News. Kasim Kutay When asked about possible site closures or layoffs, Kutay said the team hasn’t thought… #lucidquest #genetherapy #celltherapy

I find the article below very interesting for two reasons. First, I wholeheartedly agree with #Biocon's CEO that launching an #adalimumab #biosimilar isn't about dominating that particular market, but about getting a piece of the pie, because "It’s a very large opportunity, and even a small market share is a large value.” In the event all (or most) of the ABs launched in the US and market share was distributed evenly, they each could be billion-dollar drugs (even when accounting for market share loss to other products, such as #Skyrizi and #Rinvoq). The second interesting piece is their marketing plan based on their dual-pricing strategy. High-list/high-rebate may be more attractive to payers, while a low-list price is more for organizations involved with GPOs. However, I'm still uncertain on which pricing strategy will benefit the patients, and overall drug spending, more. Christopher Miller Shaila Yoshida https://lnkd.in/ey4W4BwD

Big news in biotech: Novo Holdings is acquiring Catalent, signaling the market's strong confidence in life sciences. This deal transcends mere financial metrics; it represents a strategic response to the bottleneck in peptide production. Peptides play a crucial role in therapeutic development today, and our endeavors at Lactocore Group with easily synthesized peptides foreshadow a future where supply aligns with demand. E.g. our drug, CHM-273, targets metabolic disorders (T2D, obesity) and features appetite control. Therefore, Novo Nordisk, with our peptide, you won't need to consider acquiring additional plants 😉 https://lnkd.in/eapjAY2f 

It can be difficult to keep up with all the latest advances within the field of model-informed drug development. Get up to speed with this symposium led by Vice President, Pharmacometric Services, Amparo de la Peña where experts in the field will discuss the “Latest Innovations in Model-Informed Precision Dosing Around the World.” https://lnkd.in/g8vM-gUR #Pharmacometrics #PrecisionMedicine #DrugDevelopment Ana Ruiz Erwin Dreesen Manuel Ibarra Ron Keizer Sebastian Wicha